Literature DB >> 16955243

A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo.

T A Popov1, D Dumitrascu, A Bachvarova, C Bocsan, V Dimitrov, M K Church.   

Abstract

BACKGROUND: The histamine-induced wheal and flare response was used to compare quantitatively the antihistaminic potency of levocetirizine and desloratadine.
METHODS: In this double-blind, placebo-controlled crossover study, 24 healthy male non-atopic volunteers received weekly single doses of 1.25, 2.5 or 5 mg levocetirizine, 2.5, 5 or 10 mg desloratadine, or placebo. Four hours after dosing, histamine (100 mg/ml) skin prick tests were performed on the volar surface of both forearms. The diameters of the wheals and flares were measured 10 minutes later. Sedation was evaluated using a visual analogue scale and a motricity test. The effects of individual drug doses were compared using Student's t-test for paired data and the overall effects of the two drugs by ANOVA.
RESULTS: All doses of levocetirizine significantly (P < 0.0001) inhibited both wheals and flares in a dose-related manner. Only the 10 mg dose of desloratadine achieved significant inhibition of response. ANOVA showed levocetirizine to be significantly (P < 0.0001) more active than desloratadine. Neither drug caused significant sedation or loss of motricity.
CONCLUSION: Levocetirizine is significantly more effective than desloratadine in inhibiting wheal and flare responses to histamine in human skin in vivo, with 1.25 mg levocetirizine being more effective than 10 mg desloratadine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16955243     DOI: 10.1007/s00011-006-0075-z

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  8 in total

1.  Pruritus: an updated look at an old problem.

Authors:  Yvette A Tivoli; Richard M Rubenstein
Journal:  J Clin Aesthet Dermatol       Date:  2009-07

2.  Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine.

Authors:  Nelly Frossard; Margherita Strolin-Benedetti; Ashok Purohit; Gabrielle Pauli
Journal:  Br J Clin Pharmacol       Date:  2007-10-29       Impact factor: 4.335

3.  Loratadine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety.

Authors:  P Anuradha; Rituparna Maiti; J Jyothirmai; Omer Mujeebuddin; M Anuradha
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

4.  Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.

Authors:  Manik Amin; Monica Desai; Kathryn Trinkaus; Amberly Brown; Andrea Wang-Gillam; Benjamin Tan; Joel Picus; Steven Sorscher; Maureen Highkin; Kim Lears; Albert C Lockhart
Journal:  J Gastrointest Oncol       Date:  2019-06

5.  The anti-inflammatory effects of levocetirizine--are they clinically relevant or just an interesting additional effect?

Authors:  Garry M Walsh
Journal:  Allergy Asthma Clin Immunol       Date:  2009-12-17       Impact factor: 3.406

6.  Pharmacology of antihistamines.

Authors:  Diana S Church; Martin K Church
Journal:  World Allergy Organ J       Date:  2011-03       Impact factor: 4.084

7.  Diagnosis and treatment of urticaria and angioedema: a worldwide perspective.

Authors:  Mario Sánchez-Borges; Riccardo Asero; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan A Bernstein; G Walter Canonica; Richard Gower; David A Kahn; Allen P Kaplan; Connie Katelaris; Marcus Maurer; Hae Sim Park; Paul Potter; Sarbjit Saini; Paolo Tassinari; Alberto Tedeschi; Young Min Ye; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2012-11       Impact factor: 4.084

8.  Challenges in the management of chronic urticaria.

Authors:  Todor A Popov
Journal:  World Allergy Organ J       Date:  2011-03       Impact factor: 4.084

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.